Can a higher dose of cabozantinib outsmart advanced kidney cancer?

NCT ID NCT05931393

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a higher dose (80 mg) of the drug cabozantinib can help people with advanced kidney cancer whose disease has worsened while on the standard dose. About 18 participants will receive the higher dose daily. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib (higher dose)
What this could lead to: If successful, this could offer a new treatment option for patients with advanced kidney cancer who have stopped responding to standard cabozantinib.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply broadly. Higher doses may also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RCC RENAL CELL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.